GSK 2862277

Drug Profile

GSK 2862277

Alternative Names: 2862277; GSK2862277

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibodies
  • Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury

Most Recent Events

  • 08 Nov 2017 GlaxoSmithKline terminates a phase II trial due to protocol defined stopping criteria not met in Acute lung injury in United Kingdom (Inhalation) (NCT02221037)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-lung-injury(In volunteers) in United Kingdom (IV, Infusion)
  • 01 Apr 2015 Phase-II clinical trials in Acute lung injury in United Kingdom (Inhalation) (NCT02221037)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top